Regeneron’s Gene Therapy Improves Hearing in Deaf Children

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one-time treatment.

Ten of the 11 participants who were assessed at least once experienced improved hearing at various decibel levels, according to results released Monday. Participants started the trial unable to detect the sound of a vacuum cleaner, said Jonathon Whitton, head of Regeneron’s auditory global program. After the treatment, most were able to hear barking dogs and conversations — some were even able to hear whispers.